Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Zymeworks restocks its clinical pipeline
After ZW171's exit, ZW251 enters the clinic.
